Information for "Period We Review involving Cabozantinib as well as Nivolumab Alone or even Using Ipilimumab pertaining to Advanced as well as Metastatic Urothelial Carcinoma and Other Genitourinary Malignancies"
From EECH Central
Basic information
| Display title | Period We Review involving Cabozantinib as well as Nivolumab Alone or even Using Ipilimumab pertaining to Advanced as well as Metastatic Urothelial Carcinoma and Other Genitourinary Malignancies |
| Default sort key | Period We Review involving Cabozantinib as well as Nivolumab Alone or even Using Ipilimumab pertaining to Advanced as well as Metastatic Urothelial Carcinoma and Other Genitourinary Malignancies |
| Page length (in bytes) | 3,902 |
| Page ID | 1384981 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Eyesalt66 (Talk | contribs) |
| Date of page creation | 09:53, 20 April 2024 |
| Latest editor | Eyesalt66 (Talk | contribs) |
| Date of latest edit | 09:53, 20 April 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
